Day: June 30, 2021

Company announcement  Holmens Kanal 2-12DK-1092 København KTel. +45 45 14 14 00 30 June 2021Notes with a coupon payment linked to the EURO Stoxx 50 Price index On 1 July 2021, Danske Bank will issue EUR 126,000 in notes with a coupon payment linked to the performance the EURO Stoxx 50 Price index. The notes are designated “DB European Autocallable 2026”, (ISIN: DK0030492723). The notes are issued at a price of 100. The notes pay interest as determined by reference to the development of the EURO Stoxx 50 Price index. The notes are issued under Danske Bank’s EUR 5,000,000,000 Structured Note Programme dated 16 June 2021. For further information about the notes, please see the Final Terms attached to this announcement which together with the Base Prospectus specify the terms and conditions of the notes. Danske Bank A/S Contact: Michael...

Company announcement no 6 2021  Danske Bank A/SHolmens Kanal 2 – 12DK – 1092 København KTel. +45 45 14 00 00 30 June 2021Danske Bank A/S to merge MobilePay with Norwegian Vipps and Finnish Pivo Danske Bank A/S has entered into an agreement with OP Financial Group in Finland and the consortium of banks behind Vipps in Norway to merge the three mobile payment providers MobilePay, Vipps and Pivo. The ambition is to create Europe’s best and most comprehensive digital wallet. Serving 11 million users and over 330,000 shops and web shops, the company will be one of the largest bank-owned mobile payment providers in Europe. The parties wish to join forces to further strengthen product development and innovation and thereby provide a market-leading customer experience within payment solutions – while at the same time giving personal...

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 30 JUNE 2021 9.30 A.M. EET, MANAGER’S TRANSACTIONOma Savings Bank Plc: Manager´s Transactions – Timo Kokkala Person subject to the notification requirements: Name: Kokkala TimoPosition: Member of the Board/Deputy Member Issuer: Oma Savings Bank PlcLEI: 743700LE1ECAPXC5UT18Notification type: INITIAL NOTIFICATIONReference number: 743700LE1ECAPXC5UT18_20210629182043_2Transaction date: 2021-06-29Venue: NASDAQ HELSINKI LTD (XHEL)Nature of the transaction: ACQUISITIONInstrument type: SHAREISIN: FI4000306733 Transaction details (1): Volume: 800 Unit price: 13.65 EUR Aggregated transactions(1): Volume: 800 Volume weighted average price: 13.65 EUROma Savings Bank PlcFurther enquiries:Pasi Sydänlammi, CEO, tel. +358 45 657 5506Minna Sillanpää, CCO, tel. +358 50 66592 Distribution:Nasdaq Helsinki...

In accordance with the resolution at the 2021 Annual General Meeting, cancelation of own shares and a bonus issue, where no new shares were issued, were registered by The Swedish Companies Registration Office (Bolagsverket) in June 2021. Fingerprint Cards AB’s registered share capital remained unchanged, but the number of shares and voting rights decreased. After cancelation of 15,967,675 B-shares which had been bought back following a resolution at the 2020 Annual General Meeting, the number of shares amount to 298,000,000, whereof 6,000,000 are A-shares and 292,000,000 are B-shares. The total number of voting rights amount to 358,000,000. The share capital remains unchanged after the bonus issue and amounts to SEK 12,975,667. For information, please contact: Investor Relations: +46(0)10-172 00 10, investrel@fingerprints.com Press: +46(0)10-172...

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer –   GENEVA, Switzerland and BOSTON – June 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced clinical data from a pilot study on Yselty® (linzagolix) for the treatment of severe adenomyosis was presented at the European Society of Human Reproduction and Embryology (ESHRE) Virtual 37th Annual Meeting, being held June 26-July 1, 2021. Additionally, 52-week data from two Phase 3 studies of Yselty for the treatment of uterine fibroids, as well as results from an analysis of uterine contractility in women who...

MINNEAPOLIS, June 30, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,333,334 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company has granted to the underwriter a 30-day option to purchase...

MONTREAL, June 29, 2021 (GLOBE NEWSWIRE) — Xebec Adsorption Inc. (TSX: XBC) (“Xebec”), a global provider of clean energy solutions, announces that all eight (8) nominees listed in the management information circular dated May 18, 2021 (the “Circular”), were elected as directors of Xebec at its Annual and Special Meeting of Shareholders which was held on virtually on Tuesday, June 29, 2021. Each of the directors was elected by a majority of the votes cast by shareholders present or represented by proxies at the meeting, as follows:Name of Nominee   For   Withhold    Votes %   Votes %William Beckett   50,147,996 90.735   5,120,789 9.265Peter Bowie   47,955,650 86.768   7,313,135 13.232Sara Elford   47,958,395 86.773   7,310,390 13.227Karen Nielsen   55,195,631 99.868   73,154 0.132Guy Saint-Jacques   47,206,169 85.412   8,062,616 14.588Ouma...

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the pricing of its upsized initial public offering of 8,682,142 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. In addition, Aerovate has granted the underwriters a 30-day option to purchase up to an additional 1,302,321 shares of common stock at the initial public offering price per share, less the underwriting discounts and commissions. All of the shares are being offered by Aerovate. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable...

CALGARY, Alberta, June 29, 2021 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) announces the results of voting on matters submitted to shareholders at the Company’s annual meeting held today. Election of Directors At the meeting, each of Patrick McDonald, Mimi Lai, Derek Petrie, Ajay Sabherwal and Rob Wonnacott was nominated for election as a director of the Company for the ensuing year. Each such nominee was elected by ordinary resolution, for a term of office ending at the close of the next annual meeting of shareholders. The term of office of William Roach, who had served as a director of Prairie Provident since 2018, concluded at the meeting. Dr. Roach decided to retire from the Board of Directors and did not stand for re-election. “On behalf of...

HALIFAX, Nova Scotia, June 29, 2021 (GLOBE NEWSWIRE) — MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2021. Profit and Loss HighlightsRevenue: The Company recorded revenues in Q3 FY2021 of $64,631 compared to $87,207 in Q3 FY2020. Gross Profit: The Company recorded a gross profit in Q3 FY2021 of $30,884 compared to $70,344 for the same period last year. The overall gross margin percentage on sales decreased by 33% from 80% in Q2 FY2020 to 47% in this financial quarter. This decrease was solely due to an extraordinary inventory adjustment in this quarter. Operating expenses: The Company recorded for this quarter operating expenses of $233,300 compared to $602,996 in Q3 FY2020. Net loss: The Company recorded a net loss of $338,053 compared to $692,479 in Q3 FY2020. The...